Potent and selective inhibitor of catechol-O-methyl-transferase.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 200.11. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5 mL||24.99 mL||49.97 mL|
|5 mM||1 mL||5 mL||9.99 mL|
|10 mM||0.5 mL||2.5 mL||5 mL|
|50 mM||0.1 mL||0.5 mL||1 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Mannisto and Kaakola (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol.Toxicol. 66 317 PMID: 2196554
If you know of a relevant reference for OR-486, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Catechol O-methyl transferase COMT inhibitors inhibits Catechol O-Methyltransferase
1 Citation for OR-486
Citations are publications that use Tocris products. Selected citations for OR-486 include:
Oróstica et al (2014) Estradiol increases cAMP in the oviductal secretory cells through a nongenomic mechanism. Reproduction 148 285 PMID: 25038866
Do you know of a great paper that uses OR-486 from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.